MedTrace Logo

Prophylactic Infusion of Donor Lymphocytes in Cord Blood Transplantation

NCT02328885 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2021-12-08

No results posted yet for this study

Summary

Pilot, multicentric, open-label, single-arm, phase I-II clinical trial to evaluate the safety and efficacy of a novel Umbilical Cord Blood Transplantation (UCBT) platform, that consists of a UCBT of the 80 fraction, followed by a Donor Lymphocyte Infusion (DLI) of the 20 fraction (between 60 and 90 days after transplantation).

Conditions

Interventions

DRUG

DLI of the 20 fraction of the UCBT

Administration of 20 fraction of the UCBT

Sponsors & Collaborators

  • Hospital Vall d'Hebron

    collaborator OTHER

  • Hospital de Sant Pau

    collaborator OTHER

  • Hospital Universitari de Bellvitge

    collaborator OTHER

  • Germans Trias i Pujol Hospital

    collaborator OTHER

  • Fundacion IMIM

    collaborator OTHER

  • Banc de Sang i Teixits

    lead OTHER

Principal Investigators

  • Sergio Querol, PhD · Banc de Sang i Teixits

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2017-03-22
Completion
2017-03-22

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02328885 on ClinicalTrials.gov